Stifel Nicolaus Reiterates Their Buy Rating on Esperion (ESPR)

By Carrie Williams

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Esperion (ESPRResearch Report), with a price target of $70. The company’s shares closed last Monday at $36.78, close to its 52-week low of $33.13.

Archila commented:

“We are reiterating our Buy rating and lowering our target price to $70 which reflects a more conservative pre-CVOT BPA/combo sales ramp and higher SG&A assumptions. Even with our more conservative forecasts, we believe ESPR is undervalued at these levels (EV of ~$700 million) as we think the stock continues to reflect investor skepticism on the commercial opportunity for BPA/ combo and the company’s cash runway. We view BPA/combo as a clinically de-risked asset with two upcoming and believe BPA’s CVOT design portends a high probability of success. Further, our recent KOL checks have been consistent with our past discussions (see deep dive) in validating what we believe is a meaningful commercial opportunity for BPA/combo in the statin intolerant population.”

According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.0% and a 30.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Esperion with a $78.75 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $60.99 and a one-year low of $33.13. Currently, Esperion has an average volume of 434.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.